

Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/25**

DaxibotulinumtoxinA-lanm (Daxxify™)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

- The treatment of cervical dystonia in adult patients.

All other indications are considered experimental/investigational and not medically necessary.

EXCLUSIONS

Coverage will not be provided for cosmetic use.

CRITERIA FOR INITIAL APPROVAL

Cervical dystonia

Authorization of 12 months may be granted for the treatment of adults with cervical dystonia (e.g., torticollis) when both of the following are met:

- Member is 18 years of age or older
- There is abnormal placement of the head with limited range of motion in the neck

CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria and be experiencing benefit from therapy.

MEDICATION QUANTITY LIMITS

Drug Name	Diagnosis	Maximum Dosing Regimen
Daxxify (DaxibotulinumtoxinA-lanm)	Cervical Dystonia	Route of Administration: Intramuscular ≥18 year(s) 250Units divided among the affected muscles. May re-treat no sooner than every 12 weeks.

Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/25**

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Daxxify [package insert]. Newark, CA: Revance Therapeutics, Inc; November 2023.

EFFECTIVE DATE 10/31/2025

ID_CHS